PARK INNOVAARE

Blog

Corporate Innovation Makeover: Excubation rules 3 and 4

Building on the excubation conversation we started in this blog series, and having introduced first two rules of the approach, we dive here into the next...

More details More details

Unprecedented speed and success rate with delivering ligand-bound GPCR structures

Modern drug discovery greatly benefits from knowledge of how a drug interacts with its molecular drug target. Membrane protein drug targets represent a...

More details More details

How can KPI steer your innovation process?

PARK INNOVAARE works at the interface of technology-driven companies and public research, such as at the nearby Paul Scherrer Institute (PSI). In one of...

More details

Methodically secret: what should you consider with respect to your know-how and trade secrets?

It falls short of a full appreciation of innovation to consider only patentable inventions. Process innovation, for instance, is usually not patentable....

More details

Radio-diagnosis paves the way for better therapy

In March 2017, the Strategy Committee at the Paul Scherrer Institute (PSI) gave its green light for a joint initiative with PARK INNOVAARE to join in realizing...

More details

Crystallization at its best

The success of many R&D projects in the pharmaceutical, chemical or agro industries depends on the exact and complete knowledge of a sample. To deliver...

More details

Electron diffraction opens new possibilities for structure-based drug discovery

Modern pharmaceutical development is tailored to the chemical and physical characteristics of active organic compounds. The reason why the atomic structure...

More details

State-of-the-art bioinformatics for better drug discovery

The effect a drug has on the human body depends on how well its active substance find its way to the targeted cells in the body, and on the chemical reactions...

More details

The value of the absolute structure

The exact knowledge and understanding of a molecule’s structure underpin all the substantial progress in chemical, agrarian and pharmaceutical research....

More details

leadXpro “unlocks” new targets for structure-based drug discovery

One of the most promising groups of drug targets is that of integral membrane proteins. They are responsible for communicating signals from the outside...

More details

Biosensors Technology Platform for efficient lead discovery

In April 2016, the team at InterAx Biotech AG mounted the nameplate of a newly-born company on the wall of PARK INNOVAARE’s deliveryLAB, thus giving...

More details

Dr. Markus Anding: "We are trying to find innovative ways to innovate."

Interview with Dr. Markus Anding, co-founder and Managing Director at Excubate Corporate Startups In our highly competitive world, companies need to...

More details